Will Rescheduling Hydrocodone Combination Products Actually Reduce Abuse?

Published Online: Thursday, January 16, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, argues that categorizing hydrocodone combination products as Schedule II drugs is unlikely to reduce abuse of the medications.

This is the part of a series of videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)

These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Reclassifying hydrocodone will not stop the drug from being filled legitimately and sold illegally.
Just a dozen drug ingredients are the culprits behind nearly half of all emergency hospitalizations for unsupervised prescription drug ingestions among young children.
In its statement, NACDS emphasized chain pharmacy’s initiatives to comply with DEA’s “cradle-to-grave” regulation structure.
Supporters of the upcoming rescheduling of hydrocodone combination products believe it will help curb our drug abuse and addiction problem in the United States. I don't think so. This article explains why.
Latest Issues
$auto_registration$